Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14862084 | 0.79 | SMN1; SMN2 (0.47) | KDM4EKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL15938054 | 0.76 | SMN1; SMN2 (0.44) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14862371 | 0.76 | KDM4E (0.47) | KDM4EKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL15938290 | 0.75 | HTT (0.44) | KDM4EKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL14861964 | 0.75 | AURKA (0.45) | KDM4EKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL14862217 | 0.74 | KDM4E (0.48) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14861709 | 0.74 | ALDH1A1 (0.53) | KDM4EKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL14861647 | 0.73 | KMT2A (0.53) | KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15938793 | 0.73 | PTGES (0.43) | KDM4EKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL14862377 | 0.73 | KDM4E (0.43) | KDM4EKMT2AMEN1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766342-B1 | PHENYL-GUANIDINE DERIVATIVES | UNIV NAC QUILMES (AR) | 2016-02-10 | — | — | EP | claimed |
| US-9783501-B2 | Substituted quinolines as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-9139529-B2 | Substituted quinoxalines as sodium channel modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, SCN2A | KDM4E 2141/4885KMT2A 1945/4885MEN1 2358/4885 |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, SCN2A | KDM4E 2141/4885KMT2A 1945/4885MEN1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.